» Articles » PMID: 26863116

An Appraisal of Proliferation and Apoptotic Markers in Papillary Thyroid Carcinoma: An Automated Analysis

Overview
Journal PLoS One
Date 2016 Feb 11
PMID 26863116
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Proliferation and apoptosis are opposing processes by which the cell numbers are kept in a delicate balance, essential for tissue homeostasis, whereas uncontrolled growth of cells is a hallmark of cancer. Papillary thyroid cancer (PTC) is the commonest type of thyroid cancer, with some PTC following an indolent course, whereas the other ones are more aggressive.

Aim: To evaluate respective contribution of proliferation and apoptosis in the tumorigenesis of PTC by automated analysis.

Materials And Methods: We investigated the immunolabeling of phosphorylated histone H3 (pHH3), cyclin D1, active caspase-3, and bcl-2 in thirteen cases each of metastatic PTC, follicular variant of PTC (FVPTC), papillary microcarcinoma (PMC) and well differentiated tumor of uncertain malignant potential (WDT-UMP). FVPTC cases comprised seven encapsulated and six unencapsulated cases.

Results: Proliferation, as assessed by pHH3 and cyclin D1 immunolabeling, was increased in all PTC variants, including the putative precursor lesion WDT-UMP, compared to normal thyroid tissue. pHH3 was immunolabeled in more cells of metastatic PTC than of PMC and of encapsulated FVPTC. Surprisingly, metastatic PTC and unencapsulated FVPTC also demonstrated more cleaved caspase-3 immunolabeled cells than the other types. In contrast, increased expression of bcl-2 protein was seen in normal thyroid areas, encapsulated FVPTC and PMC as compared to metastatic PTC. Metastatic PTC shows higher proliferation than other types of PTC but unexpectedly also higher apoptotic levels. Similar results were also seen with unencapsulated FVPTC, thus suggesting that unencapsulated FVPTC has a potential for adverse outcome. Bcl-2 was immunolabeled in a low percentage of cells in WDT-UMP.

Conclusions: The expression of the proliferative protein pHH3 together with the apoptotic marker cleaved caspase-3 may indicate an aggressive behaviour of PTC and loss of apoptosis inhibition by bcl-2 protein can further amplify the role of these proteins in tumor progression. Both cyclin D1 and bcl-2 could prove to be interesting markers of PTC precursor lesions. Automated/digital image quantification approach helps in refining the diagnostic accuracy.

Citing Articles

Clinical, Pathological, and Immunohistochemical Predictors of Cause-Specific Mortality in Papillary Thyroid Cancer: Multivariate Analysis.

Bakarev M, Ivanov A, Lushnikova E Bull Exp Biol Med. 2024; 177(3):353-358.

PMID: 39134811 DOI: 10.1007/s10517-024-06188-8.


A systematic review and meta-analysis comparing tumor progression and complications between radiofrequency ablation and thyroidectomy for papillary thyroid carcinoma.

Sun Y, Zhang H, Zhu H, Wu C, Chen M, Han J Front Oncol. 2022; 12:994728.

PMID: 36530996 PMC: 9748571. DOI: 10.3389/fonc.2022.994728.


HIF-1α and Caspase-3 expression in aggressive papillary thyroid carcinoma.

Zhang L, Shi B, Hu M, Qian L World J Surg Oncol. 2022; 20(1):353.

PMID: 36329448 PMC: 9635136. DOI: 10.1186/s12957-022-02815-8.


Lowered levels of microRNA-129 and potential signaling pathways in papillary thyroid carcinoma: a determination of microRNA sequencing in 507 patients and bioinformatics analysis.

Liang L, Luo Y, Yang X, Zhang R, Wang H, Yang H Int J Clin Exp Pathol. 2020; 10(7):7511-7527.

PMID: 31966595 PMC: 6965262.


Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.

Cui D, Zhao Y, Xu J Cancer Biol Ther. 2018; 20(5):608-616.

PMID: 30404567 PMC: 6606038. DOI: 10.1080/15384047.2018.1539289.


References
1.
Liu J, Singh B, Tallini G, Carlson D, Katabi N, Shaha A . Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006; 107(6):1255-64. DOI: 10.1002/cncr.22138. View

2.
Muller-Hocker J . Immunoreactivity of p53, Ki-67, and Bcl-2 in oncocytic adenomas and carcinomas of the thyroid gland. Hum Pathol. 1999; 30(8):926-33. DOI: 10.1016/s0046-8177(99)90246-0. View

3.
Song Q, Wang D, Lou Y, Li C, Fang C, He X . Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011; 6:126. PMC: 3264507. DOI: 10.1186/1746-1596-6-126. View

4.
Chan J . Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002; 117(1):16-8. DOI: 10.1309/P7QL-16KQ-QLF4-XW0M. View

5.
Trovisco V, Soares P, Preto A, Castro P, Maximo V, Sobrinho-Simoes M . Molecular genetics of papillary thyroid carcinoma: great expectations. Arq Bras Endocrinol Metabol. 2007; 51(5):643-53. DOI: 10.1590/s0004-27302007000500002. View